FDA Workshop Explores Needs for Faster Interchangeable Biosimilars Development
Published Date: 8/15/2025
Notice
Summary
The FDA is hosting a public workshop to explore how to make interchangeable biosimilar products better and easier to develop. This affects drug makers and patients who want more affordable medicine options. The workshop is part of a plan running through 2027 and aims to gather ideas on future research and guidance, potentially speeding up access and saving money.
Analyzed Economic Effects
1 provisions identified: 1 benefits, 0 costs, 0 mixed.
Workshop on Interchangeable Biosimilars
The FDA is holding a public workshop titled "Advancing the Development of Interchangeable Products: Identifying Future Needs" as part of its Biosimilar User Fee Act (BsUFA) III commitments for fiscal years 2023 through 2027. The workshop will gather ideas on guidance and research that the FDA says may help make interchangeable biosimilar drugs easier to develop, which could speed patient access and help lower costs for people seeking more affordable medicines.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in